| Barahona-Garrido J, Yamamoto-Furusho JK
New treatment options in the management of IBD - focus on colony stimulating factors. [Journal Article]
Biologics 2008 Sep; 2(3):501-4.
Abstract | Full Citation | Find Related Articles | | Heaney ML, Toy EL, Vekeman F, et al.
Comparison of hospitalization risk and associated costs among patients receiving sargramostim, filgrastim, and pegfilgrastim for chemotherapy-Induced neutropenia. [JOURNAL ARTICLE]
Cancer 2009 Jul 27.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Sauvé S, Gingras G, Aubin Y
NMR assignment of human granulocyte-macrophage colony-stimulating factor. [Journal Article]
Biomol NMR Assign 2008 Jun; 2(1):5-7.
Abstract | Full Citation | | McNeel DG, Dunphy EJ, Davies JG, et al.
Safety and Immunological Efficacy of a DNA Vaccine Encoding Prostatic Acid Phosphatase in Patients With Stage D0 Prostate Cancer. [JOURNAL ARTICLE]
J Clin Oncol 2009 Jul 27.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Drake CG
Immunotherapy for Prostate Cancer: Walk, Don't Run. [JOURNAL ARTICLE]
J Clin Oncol 2009 Jul 27.
Full Citation | Find Related Articles | | Huggett B
Genzyme takes Campath bet. [News]
Nat Biotechnol 2009 Jun; 27(6):498.
Full Citation | Publisher Full Text | Find Related Articles | | Valentine JF, Fedorak RN, Feagan B, et al.
Steroid-sparing Properties of Sargramostim in Patients With Corticosteroid-dependent Crohn's disease: A Randomised, Double-blind, Placebo-controlled, Phase 2 Study. [JOURNAL ARTICLE]
Gut 2009 Jun 7.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Spitler LE, Weber RW, Allen RE, et al.
Recombinant Human Granulocyte-macrophage Colony-stimulating Factor (GM-CSF, Sargramostim) Administered for 3 Years as Adjuvant Therapy of Stages II(T4), III, and IV Melanoma. [JOURNAL ARTICLE]
J Immunother 2009 May 28.
Abstract | Full Citation | | Takazoe M, Matsui T, Motoya S, et al.
Sargramostim in patients with Crohn's disease: results of a phase 1-2 study. [JOURNAL ARTICLE]
J Gastroenterol 2009 Apr 8.
Abstract | Full Citation | | Lutzky J, Weber R, Nunez Y, et al.
A phase 1 study of granulocyte macrophage colony-stimulating factor (sargramostim) and escalating doses of thalidomide in patients with high-risk malignant melanoma. [Journal Article, Research Support, Non-U.S. Gov't]
J Immunother 2009 Jan; 32(1):79-85.
Abstract | Full Citation |   |
|
| |
Advertise on this site.
|
